Released Sep 14, 2018, after the close
10-Q filed Sep 14, 2018, 45 days after period end · 0001654954-18-010198
Q3 2018 · 10-Q
Revenue$4.63M$4.63M +16.4% vs Q3 2017+23.0% vs Q2 2018
Net Income$730.63K$730.63K N/M vs Q3 2017N/M vs Q2 2018
EPS Diluted$0.03$0.03 N/M vs Q3 2017N/M vs Q2 2018
Gross Profit$1,593,848+71.7%
Operating Income$721,819N/M
Operating Cash Flow$1,685,270N/M
Free Cash Flowderived$1,685,270N/M
Margins · derived
Gross margin34.4%+11.1 pt vs Q3 2017
Operating margin15.6%+20.5 pt vs Q3 2017
Net margin15.8%+19.9 pt vs Q3 2017
What the release said
The release
Same quarter
| Metric | Q3 2018 | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|---|
| Revenue | $4.63M | $3.98M | — | — |
| Net Income | $730.63K | -$162.98K | -$130.47K | $453.97K |
| EPS Diluted | $0.03 | -$0.01 | -$0.01 | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR